Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

SOTALOL HCL

All products: not a benefit

Other products in the same Health Canada class (C07A, C07AA) — coverage varies; not interchangeable

  • Nadolol (Corgard): general benefit, Not a benefit
  • Propranolol (Inderal-LA): general benefit, Not a benefit
  • Timolol (Blocadren): general benefit, Not a benefit
  • Acebutolol (Sectral): general benefit, Not a benefit
  • Atenolol (Apo-Atenol): general benefit
  • Bisoprolol (Sandoz Bisoprolol Tablets): general benefit, Not a benefit

3 more in the class list below

Sotacor · DIN 00483923 · 160mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2005-08-01 — choose a marketed DIN from the same-category list.Discontinued 2005-08-01 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2005-08-01 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2005-08-01 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Sotacor · DIN 00483923 Manufacturer: Bristol Myers Squibb Canada Inc; listing date 1996-10-01 Health Canada: Cancelled post market since 2005-08-01 · brand SOTACOR TAB 160MG · ATC C07AA07 SOTALOL · form Tablet · route Oral · ingredients SOTALOL HYDROCHLORIDE 160 MG · company Bristol labs division of bristol-myers squibb · schedule Prescription
Check this DIN again · Health Canada product record

Sotacor: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=6176 · Verify on the e-Formulary ↗ (DIN 00483923)

Source record
DIN 00483923: Sotacor Raw flags: chronicUseMed=Y, notABenefit=Y, sec3=Y Item: 240400068; group id 291; item number 0631; lccId None; manufacturer id BQU Source form: Tab; strength: 160mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00483923 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=6176
Interchangeable products
AMB-Sotalol · DIN 02565412 · $0.1623 Apo-Sotalol · DIN 02167794 · $0.1623 Jamp-Sotalol · DIN 02368625 · $0.1623 PMS-Sotalol · DIN 02238327 · $0.1623
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00483923
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2005-08-01 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (24:04 Cardiac Drugs) and how they are covered

Matched class: 24:04 Cardiac Drugs

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ATENOLOL, DIGOXIN, PROPAFENONE HCL Some products covered without a code (check the product listing): ACEBUTOLOL HCL, AMIODARONE HCL, AMLODIPINE, BISOPROLOL FUMARATE, DILTIAZEM HCL, DISOPYRAMIDE, FLECAINIDE ACETATE, METOPROLOL TARTRATE, MEXILETINE HCL, NADOLOL, NIFEDIPINE, PROPRANOLOL, TIMOLOL MALEATE, VERAPAMIL HCL 24:00 CARDIOVASCULAR DRUGS

RANOLAZINE

· 2 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 500mg · ER Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 24:00 24:04 Cardiac Drugs

NADOLOL

· 8 products · Listed, not a benefit (3), General benefit (5) · strengths: 40mg, 80mg, 160mg · Tab

PROPRANOLOL

· 19 products · Off-Formulary Interchangeable, not an ODB benefit (8), General benefit (7), Listed, not a benefit (4) · strengths: 60mg, 80mg, 120mg, 160mg, 10mg, 20mg, 40mg · LA Cap, Tab

TIMOLOL MALEATE

· 6 products · Listed, not a benefit (3), General benefit (3) · strengths: 5mg, 10mg, 20mg · Tab

ACEBUTOLOL HCL

· 9 products · Listed, not a benefit (3), General benefit (6) · strengths: 100mg, 200mg, 400mg · Tab

ATENOLOL

· 26 products · General benefit · strengths: 50mg, 100mg · Tab

BISOPROLOL FUMARATE

· 20 products · General benefit (18), Listed, not a benefit (2) · strengths: 1.25mg, 2.5mg, 5mg, 10mg · Tab

METOPROLOL TARTRATE

· 28 products · Listed, not a benefit (6), General benefit (22) · strengths: 100mg, 200mg, 50mg · LA Tab, Tab

CARVEDILOL

· 36 products · Listed, not a benefit (4), Limited Use, codes 183 (32) · strengths: 3.125mg, 6.25mg, 12.5mg, 25mg · Tab

NEBIVOLOL HYDROCHLORIDE

· 8 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 2.5mg, 5mg, 10mg, 20mg · Tab

AMIODARONE HCL

· 9 products · Listed, not a benefit (1), General benefit (8) · strengths: 200mg · Tab

AMLODIPINE

· 56 products · Limited Use, codes 645, 706 (1), Off-Formulary Interchangeable, not an ODB benefit (11), General benefit (44) · strengths: 1mg/mL, 2.5mg, 5mg, 10mg · Oral Sol, Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 24:04 and 9 more
Full class listing Related classes: 24:06 Antilipemic Drugs, 24:08 Hypotensive Drugs (For Diuretics See 40:28), 24:12 Vasodilating Drugs, 24:32 Renin-Angiotensin Aldosterone Inhibitors Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: documented symptomatic ventricular arrhythmias
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. Covered without a code on the Ontario formulary: PROPAFENONE HCL MEXILETINE HCL · Listed, not a benefit (2), General benefit (4) • the treatment of patients with documented symptomatic ventricular arrhythmias when the symptoms are of sufficient severity to require treatment. Because of the proarrhythmic effects of mexiletine, its use should be reserved for patients in whom, in the opinion of the physician, the benefit of treatment clearly outweighs the risks. PM: https://pdf.hres.ca/dpd_pm/00073596.PDF; date November 27, 2023; DIN 02230359; fetched 2026-09-10 Product monograph PROPAFENONE HCL · General benefit RYTHMOL® may also be used for the treatment of patients with documented symptomatic ventricular arrhythmias when the symptoms are of sufficient severity to require treatment. PM: https://pdf.hres.ca/dpd_pm/00062661.PDF; date August 26, 2021; DIN 00603708; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE No antiarrhythmic drug has been shown to reduce the incidence of sudden death in patients with asymptomatic ventricular arrhythmias. Most antiarrhythmic drugs have the potential to cause dangerous arrhythmias; some have been shown to be associated with an increased incidence of sudden death. In light of the above, physicians should carefully consider the risks and benefits of antiarrhythmic therapy for all patients with ventricular arrhythmias. APO-SOTALOL (sotalol hydrochloride) is indicated for the treatment of documented life- threatening ventricular arrhythmias such as sustained ventricular tachycardia. APO-SOTALOL may also be used for the treatment of patients with documented symptomatic ventricular arrhythmias when the symptoms are of sufficient severity to require treatment. Because of the proarrhythmic effects of APO-SOTALOL, its use should be reserved for patients in whom, in the opinion of the physician, the benefit of treatment clearly outweighs the risks. For patients with sustained ventricular tachycardia, APO-SOTALOL therapy should be initiated in the hospital. Hospitalization may also be required for certai… https://pdf.hres.ca/dpd_pm/00066796.PDF PM date: July 22, 2022 Source product: APO-SOTALOL; DIN 02167794; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Other review policies

For Sotacor: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026